Samsung Biologics deploys Starlims
Samsung Biologics has selected Starlims to assure on-going compliance with biologics manufacturing quality standards at its state-of-the-art biologics development and production facility in Incheon, Korea. The new facility will develop and manufacture a wide range of biologics products through genetic engineering technologies, cell culturing and purification. By 2013, Samsung Biologics will offer a broad range of mammalian cell based, cGMP manufacturing services for cell line development, process and analytical development, clinical and commercial manufacturing, as well as aseptic fill and finish operations.
‘Our biologics facility is capable of producing high quality bulk drug products,’ said Ming fang Hong, quality control team leader at Samsung Biologics. ‘We are pleased that our quality control department is relying on Starlims’ leading edge laboratory informatics solutions to help guarantee that all process and final production are high quality, meet global regulatory standards and maximise customer satisfaction.’